Stay updated with breaking news from Charles Licata. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This report describes safety monitoring after a Pfizer-BioNTech booster vaccination among children and adolescents aged 12-17 years.
This report describes safety monitoring after a Pfizer-BioNTech booster vaccination among children and adolescents aged 12-17 years.
This report describes how local and systemic reactions and myocarditis are less frequent after a homologous COVID-19 booster dose.
This descriptive study compares the effect of mRNA-based COVID-19 vaccination with BNT162b2 (Pfizer-BioNTech) vs mRNA-1273 (Moderna) on the reported cases of my
VAERS received and processed ††† 13,725 adverse event reports for Janssen COVID-19 vaccine recipients; median age was 42 years, and 66% were women (Table 1). Among these VAERS reports, 13,294 (97%) were classified as nonserious, and 343 (3%) were classified as serious, including three reports of non-CVST TTS (no deaths). Two of the TTS cases occurred among women aged 30–39 years and one in a woman aged 50–59 years. Each of these women had evidence of large-vessel thrombosis and thrombocytopenia (Table 2). As of April 25, 14 CVST cases had been confirmed ( 8), for a total of 17 TTS c...